Is Nanox.AI worth it for a mid-size imaging center?

If you process a high volume of routine CT scans, Nanox.AI can add value by detecting incidental findings that generate follow-up revenue and improve patient care. However, pricing is opaque, and the ROI depends on your scan volume—likely 10,000+ scans per year. If you're below that, it may not justify the cost. Consider a pilot first.

Does Nanox.AI integrate with PACS?

Yes, Nanox.AI integrates with PACS, EMR, and reporting systems, and is vendor-agnostic across PACS platforms. It also works with Nuance, Microsoft, and other partners. Integration is a core part of the deployment.

How does Nanox.AI compare to Viz.ai?

Nanox.AI focuses on chronic incidental findings (cardiac calcium, osteoporosis, fatty liver) from routine CT, while Viz.ai specializes in acute conditions like stroke and pulmonary embolism, sending real-time alerts. Nanox.AI is for opportunistic screening; Viz.ai is for emergency triage. They can complement each other in a health system.

What is the cheapest Nanox.AI tier?

Nanox.AI does not publish pricing or tiers. You must contact sales for a quote. The cost is likely structured per scan or per site, with enterprise agreements for large health systems. There is no self-serve or free tier.

What are Nanox.AI's biggest limitations?

The main limitations: it only covers cardiac, bone, and liver findings—not emergency conditions like stroke or PE. It requires PACS/EMR integration. Pricing is non-transparent, and performance may need calibration for non-standard CT protocols. It's not a real-time emergency tool.

Can Nanox.AI replace a general AI radiology platform?

No, Nanox.AI is specialized for incidental chronic findings. If you need AI for a broad range of pathologies (e.g., stroke, PE, lung nodules), you'll need a multi-pathology platform or multiple point solutions. Nanox.AI is best as an addition to your existing AI arsenal.

How long does Nanox.AI take to set up?

Setup time varies: for an imaging center with existing PACS/EMR, a pilot can be live in 4-8 weeks. For a large health system, expect 3-6 months for procurement, integration, and training. The vendor handles deployment and calibration.

How do I migrate from manual screening to Nanox.AI?

There's no 'migration' from a different AI if you're starting fresh—you simply integrate Nanox.AI into your PACS and EMR. If you have existing AI tools, you'd run Nanox.AI alongside, adding its incidental findings to your reports. The vendor provides implementation support.

Is Nanox.AI good for opportunistic screening?

Yes, Nanox.AI is explicitly designed for opportunistic screening: it analyzes CT scans done for other reasons to detect chronic conditions like coronary artery calcification, vertebral fractures, and fatty liver. It's proven in real-world settings, e.g., Corewell Health found thousands of new cardiac patients.

Is Nanox.AI still active in 2026?

Nanox.AI is active in 2026 but worth monitoring — liveness 68/100. Its weakest signal is what users say about it.

Healthcare

Nanox.AI

Nanox.AI reads routine CT scans to flag coronary calcification, osteoporosis risk, and fatty liver disease before symptoms appear.

68/100MonitorCustom pricingContact Sales

Nanox.AI picks a lane — incidental chronic-disease findings on CT scans you already took — and executes it with published outcomes most competitors can't match. The Corewell numbers (268 CAC reports over two years, then nearly 4,000 in one) are the kind of before-and-after that makes a business case write itself. Buy it if that lane is your priority; skip it if you need broad pathology coverage.

Verified 16d ago · liveness 68/100 · cite: rightaichoice.com/tools/nanox-ai

Best for

Radiology departments at mid-to-large health systems flagging undiagnosed cardiac, bone, or liver disease from existing CT volume
IDNs building a preventive-care standard while generating downstream revenue from clinical workup and treatment
Imaging centers adding opportunistic screening value without scheduling extra scans or patient visits
Insurers running risk adjustment by surfacing findings suggestive of chronic conditions

Not ideal for

Teams needing acute pathology detection (stroke, pulmonary embolism, trauma findings) — this is a different product category
Single-physician or very-low-CT-volume practices where the ROI math won't hold
Organizations already standardized on a broad multi-pathology radiology AI platform

Visit Website

IntermediateFor a large health system, expect 3-6 months for procurement, IT integration, and staff training. For an imaging center with existing PACS/EMR, initial pilot can be live in 4-8 weeks. Full deployment across multiple sites may take longer.WebNo public API4.3k viewsVerified 16d ago

Pricing

Custom pricing

Contact Sales4 hidden costs

Learning curve

Intermediate

For a large health system, expect 3-6 months for procurement, IT integration, and staff training. For an imaging center with existing PACS/EMR, initial pilot can be live in 4-8 weeks. Full deployment across multiple sites may take longer.

Runs on

Web

No public API · 6 integrations

Who it's for

Chief Medical Officer of a large health systemRadiology Director at a mid-size imaging centerClinical Researcher in preventive health

Live sentiment

Is Nanox.AI actually worth it?

We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.

Honest verdict, not marketing
Real pros & cons from real users
Attributed quotes with receipts

Run a free scan

3 free scans · no card needed

Skip it if

Skip Nanox.AI if you need AI for emergency findings (stroke/PE), have low CT volume where ROI won't materialize, lack PACS/EMR integration, or want a comprehensive multi-pathology AI platform.

The 30-second take

Biggest gripe

Pricing is not public; you'll need to negotiate with sales, and the initial licensing and implementation fees may be significant.

Price reality

Nanox.AI is positioned for large health systems and imaging centers that process high CT volumes, where the cost per scan becomes justifiable through revenue generation and improved outcomes. It's not designed for small practices; more affordable entry points exist with point solutions like HeartFlow or Zebra Medical, but they lack the integrated multi-pathology coverage.

In short

Nanox.AI — Nanox.AI reads routine CT scans to flag coronary calcification, osteoporosis risk, and fatty liver disease before symptoms appear. Best for Radiology departments at mid-to-large health systems flagging undiagnosed cardiac, bone, or liver disease from existing CT volume, IDNs building a preventive-care standard while generating downstream revenue from clinical workup and treatment, Imaging centers adding opportunistic screening value without scheduling extra scans or patient visits. Contact Sales pricing.

No head-to-head comparison for Nanox.AI yet — the alternatives below are the closest matches we list.

What people actually say about Nanox.AI — is it worth it?

We scanned public community sources for Nanox.AI on Sep 29, 2026 and could not establish that the discussion we found is about this tool rather than something else sharing its name. Only 0 of the posts we fetched could be positively tied to Nanox.AI. Rather than publish a sentiment score built on the wrong subject, we publish nothing here and re-run the scan.

Viability Score

68/100

Monitor

How well maintained and how widely used is Nanox.AI? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this

Recent activity

not measured

Traction

Site health

User sentiment

What the vendor publishes

Last calculated: October 2026

How we score →

Key Features

Coronary artery calcium detection on non-gated CT scans covering the full heart
HealthCCSng cardiac solution cleared via FDA 510(k) and CE marked
Vertebral height loss detection for osteoporosis on chest and abdominal CT
Bone mineral density measurement from routine chest and abdominal CT
HealthFLD liver density quantification on contrast and non-contrast CT
Liver density analysis targeting hepatic steatosis, MASLD/NAFLD, and MASH
Automated detection of incidental findings on CT scans ordered for any indication
PACS integration for in-workflow deployment
EMR integration for streamlined patient management
Automated report generation into existing reporting systems
Vendor-neutral PACS compatibility for mixed imaging environments
Opportunistic screening without additional radiation, scans, or patient visits
AI-powered second-opinion services delivered direct to patients
Real+ osteoporosis care workflow automation
Risk adjustment support for insurers via incidental chronic-condition findings

About Nanox.AI

Contact SalesIntermediateNo APIWeb

Nanox.AI is an FDA-cleared suite of incidental-findings AI that works on CT scans a patient already had — lung screening, abdominal, chest, any clinical indication. Instead of ordering new imaging, radiologists run the software in the background and surface chronic disease signals that would otherwise go unreported. The suite covers three pathologies. HealthCCSng detects coronary artery calcification on non-gated CT scans that include the entire heart, catching a significant risk factor for coronary artery disease. HealthOST flags vertebral height loss and measures bone mineral density on chest and abdominal CT, targeting osteoporosis. HealthFLD quantifies liver density on both contrast and non-contrast scans, pointing at hepatic steatosis, MASLD/NAFLD, and MASH. All three carry FDA clearance; the cardiac and bone solutions also hold CE marks. Integration is the practical pitch. The software sits alongside PACS, EMR, and reporting systems rather than replacing them, and the vendor markets vendor-neutrality across PACS — a real consideration for IDNs running mixed imaging estates. Published outcomes back this up: Corewell Health identified nearly 4,000 new cardiac patients in 2023 after the cardiac solution went live, versus 268 patients with CAC reported across the prior two years. The ADOPT study's early findings show improved spine fracture detection against the UK NHS national average. The company cites 30 million patient records, 500 million images, 22 granted patents, and 7 FDA clearances behind the platform. Nanox.AI is built for health systems, imaging centers, and insurers chasing risk adjustment — not for emergency or general multi-pathology radiology AI. If your CT volume is real and your bottleneck is undiagnosed chronic disease, this is a narrow tool doing a narrow job well.

Behind the Verdict

The pitch here is opportunistic screening, and that word matters. Nanox.AI isn't trying to read your emergency head CTs or replace your general radiology AI. It re-reads scans taken for other reasons and asks a different question: does this patient have calcification, bone loss, or a fatty liver that nobody wrote down? Where it bites is the reimbursement story. The vendor's lead demo is a US reimbursement demo, and that tells you the buy-in decision runs through billing and preventive-care workflow, not just radiology. We'd want to see the EMR handoff and report-generation path before signing — the integration claim is broad, but the operational lift lands on your IT team. Pick this when you're a mid-to-large health system or imaging center with meaningful CT volume and a preventive-care or risk-adjustment mandate. The Corewell case gives you a concrete number to bring to finance. The vendor-neutral PACS positioning also matters if you're running a mixed estate and can't stomach another single-vendor lock-in. Pass when your priority is acute pathology AI — stroke, PE, fractures on trauma scans — because that's a different product category. Solo practices with low CT throughput will struggle to justify the spend. And if you've already standardized on a broad multi-pathology platform, adding a three-condition suite means another integration surface for a narrow slice of findings. The closest mental comparison is the cohort of opportunistic-screening specialists rather than the general radiology AI platforms. Nanox.AI's advantage is the outcomes evidence and the vendor-agnostic deployment; its constraint is a fixed pathology set. If cardiac, bone, and liver are the three conditions your population needs flagged, this is a targeted fit. If your list is longer, keep

Researching Nanox.AI? Get your full AI stack in 60 seconds.

Free, no signup — tell us your goal and get tools matched to your budget & existing stack.

Real-world workflow fit

Concrete scenarios for the personas Nanox.AI actually fits — and what changes day-one when you adopt it.

Chief Medical Officer of a large health system

Wants to implement opportunistic screening to identify undiagnosed cardiac disease across the system's CT volume.

Outcome: Deploys HealthCCSng, integrates with PACS and EMR, and within months flags hundreds of at-risk patients, leading to new preventive cardiology referrals and improved population health metrics.

Radiology Director at a mid-size imaging center

Wants to differentiate by offering value-added screening without extra scans.

Outcome: Uses the full suite to add coronary calcium, osteoporosis, and fatty liver findings to every routine CT report, generating additional revenue per study and attracting referring physicians seeking comprehensive reports.

Clinical Researcher in preventive health

Studying the impact of AI-detected incidental findings on patient outcomes.

Outcome: Uses Nanox.AI's quantitative outputs to analyze cohorts, publish findings on early detection, and secure funding for expanded screening programs based on the data.

Use Cases

Identify asymptomatic coronary artery disease on routine chest CT scans
Flag vertebral compression fractures in CT scans of the thoracic or lumbar spine
Quantify hepatic steatosis in abdominal CTs for early fatty liver diagnosis
Enable opportunistic osteoporosis screening using CT bone density estimation
Generate revenue by adding screening findings to existing CT volume
Improve population health management by detecting undiagnosed chronic conditions

Models Under the Hood

Proprietary AI models for cardiac, bone, and liver detection

as of 2026-08-30

Limitations

Nanox.AI targets only cardiac, bone, and liver incidental findings—it won't flag emergent conditions like stroke or pulmonary embolism.
The platform requires integration with PACS and EMR systems; without those, it's not functional.
Pricing is not public; you must contact sales, and the cost model likely requires a minimum CT volume to achieve ROI.
Performance may need calibration for non-standard CT acquisition protocols.
There is no self-service API for custom integrations or direct developer access.

as of 2026-08-30

Verification history

We have re-verified Nanox.AI 19 times since Jun 2, 2026. Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.

Oct 2, 2026 — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Sep 22, 2026 — re-checked, vendor evidence unchanged
Aug 30, 2026 — re-checked, vendor evidence unchanged
Aug 24, 2026 — re-checked, vendor evidence unchanged
Aug 7, 2026 — re-checked, vendor evidence unchanged
Jul 31, 2026 — re-checked, vendor evidence unchanged

Showing the 6 most recent of 19 verification passes.

Free to cite with attribution — this page re-verifies continuously.

Hidden costs & gotchas

What the public pricing page doesn't put in bold. Captured from pricing-page footnotes, contract terms, and recurring complaints.

Pricing is not public; you'll need to negotiate with sales, and the initial licensing and implementation fees may be significant.
Integration with PACS, EMR, and reporting systems may require additional IT work, potentially incurring hidden consulting or project management costs.
If your CT protocols deviate from the calibrated standards, you may need to pay for additional validation and tuning services.
Ongoing maintenance, software updates, and support may be tied to an annual fee that isn't visible upfront.

Where the pricing makes sense

The company stage and team size where Nanox.AI's pricing actually pencils out — and where peers do it cheaper.

Setup time & first value

How long it actually takes to get something useful out of Nanox.AI — broken out by persona, not the marketing-page minute.

Switching to or from Nanox.AI

How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.

Migrating in

→From manual chart review or no screening: Integrate Nanox.AI with your existing PACS and EMR; the AI will run automatically on every CT, flagging incidental findings without additional human effort.

Migrating out

↗To a more comprehensive AI radiology platform: Export the AI-generated findings from your reporting system and transition to a multi-pathology vendor that covers additional modalities.

Integrations

NuanceMicrosoftCARPL.ai Harrison.aiSpinex MedicalFerrum Health

Resources & Guides

Tutorials & Learning

YouTube returned 6 videos for “Nanox.AI”, and we withheld 6: 6 could not be judged, because “Nanox.AI” is a single word that other videos use for other things. We are showing none, because we could not prove any of them are about Nanox.AI.